Two other Phase I clinical trials used pooled CAR-T cell products consisting of CD19 and CD20 CAR-T cells for diffuse large B cell lymphoma (DLBCL) (NCT02737085), and CD19 and CD22 CAR-T cells for B-cell hematologic malignancies (NCT02903810), in order to effectively control recurrence due to a CD19 escape mutation. Here, CD22 is linked to diffuse large B-cell lymphoma.